Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for NVCR

Stock NameNovocure Ltd
TickerNVCR(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINJE00BYSS4X48
LEI213800YPP55UMHWA4826

Show aggregate NVCR holdings

News associated with NVCR

NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $12.28, but opened at $13.65. NovoCure shares last traded at $13.03, with a volume of 543,802 shares trading hands. Specifically, CEO Ashley Cordova acquired 81,550 shares of the […] - 2025-09-10 02:26:51
Analysts Set NovoCure Limited (NASDAQ:NVCR) Price Target at $28.79
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average […] - 2025-08-21 04:44:51
Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer
(RTTNews) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. - 2025-08-20 08:50:20
TD Asset Management Inc Sells 204,942 Shares of NovoCure Limited (NASDAQ:NVCR)
TD Asset Management Inc decreased its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 81.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 48,212 shares of the medical equipment provider’s stock after selling 204,942 shares during the period. TD Asset Management Inc’s holdings in NovoCure […] - 2025-08-05 04:37:19
Y Intercept Hong Kong Ltd Has $419,000 Stock Position in NovoCure Limited (NASDAQ:NVCR)
Y Intercept Hong Kong Ltd raised its stake in NovoCure Limited (NASDAQ:NVCR – Free Report) by 25.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,492 shares of the medical equipment provider’s stock after buying an additional 4,723 shares during […] - 2025-07-29 05:56:52
NovoCure (NASDAQ:NVCR) Receives “Equal Weight” Rating from Wells Fargo & Company
Wells Fargo & Company reissued their equal weight rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday morning, Marketbeat reports. The firm currently has a $14.50 target price on the medical equipment provider’s stock, down from their previous target price of $40.00. Other analysts also recently issued reports about […] - 2025-07-28 04:18:52
Bank of New York Mellon Corp Purchases 2,062 Shares of NovoCure Limited (NASDAQ:NVCR)
Bank of New York Mellon Corp grew its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,592 shares of the medical equipment provider’s stock after acquiring an […] - 2025-07-25 04:35:07
32,179 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Jennison Associates LLC
Jennison Associates LLC acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,179 shares of the medical equipment provider’s stock, valued at approximately $573,000. Several other large investors also […] - 2025-07-23 06:20:54
Teacher Retirement System of Texas Acquires 3,123 Shares of NovoCure Limited (NASDAQ:NVCR)
Teacher Retirement System of Texas raised its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 62,375 shares of the medical equipment provider’s stock after purchasing an additional 3,123 shares during the quarter. Teacher Retirement System of Texas’ holdings in NovoCure were worth […] - 2025-07-14 04:56:53
LADENBURG THALM/SH SH Begins Coverage on NovoCure (NASDAQ:NVCR)
LADENBURG THALM/SH SH began coverage on shares of NovoCure (NASDAQ:NVCR – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the medical equipment provider’s stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 64.93% from the […] - 2025-07-10 04:01:26
California State Teachers Retirement System Sells 635 Shares of NovoCure Limited (NASDAQ:NVCR)
California State Teachers Retirement System reduced its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,389 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. California […] - 2025-06-06 05:42:57
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […] - 2025-06-04 03:06:44
BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)
BNP Paribas Financial Markets decreased its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 83.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,555 shares of the medical equipment provider’s stock after selling 147,371 shares during the period. BNP Paribas Financial Markets’ holdings in NovoCure were worth $851,000 as of […] - 2025-05-22 04:38:53
NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AG
Deutsche Bank AG lifted its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,327 shares of the medical equipment provider’s stock after acquiring an additional 33,293 shares during the quarter. Deutsche Bank […] - 2025-05-19 05:06:55
Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR)
Tower Research Capital LLC TRC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,034 shares of the medical equipment provider’s stock after selling 6,669 shares […] - 2025-05-12 04:50:52
NovoCure (NASDAQ:NVCR) and Meihua International Medical Technologies (NASDAQ:MHUA) Head to Head Survey
Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 1.2% of […] - 2025-05-06 02:09:04
Why NovoCure Stock Skyrocketed This Week
Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. - 2025-04-25 14:21:57
Bank of Montreal Can Acquires New Shares in NovoCure Limited (NASDAQ:NVCR)
Bank of Montreal Can purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,183 shares of the medical equipment provider’s stock, valued at approximately $244,000. Other institutional investors have also made changes to their positions in the company. Tidal Investments LLC […] - 2025-04-25 05:08:56
Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price
NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […] - 2025-04-25 04:31:12
NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com
NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other research analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of NovoCure from $42.00 to $34.00 and set an “overweight” […] - 2025-04-25 03:10:53
NovoCure Surpasses Q1 Expectations
NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s e - 2025-04-24 10:25:13
Legal & General Group Plc Reduces Stake in NovoCure Limited (NASDAQ:NVCR)
Legal & General Group Plc cut its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 157,758 shares of the medical equipment provider’s stock after selling 26,654 shares during the quarter. Legal & General Group Plc’s holdings in NovoCure were worth $4,701,000 […] - 2025-04-22 05:44:56
Summit Investment Advisors Inc. Raises Stock Holdings in NovoCure Limited (NASDAQ:NVCR)
Summit Investment Advisors Inc. boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,141 shares of the medical equipment provider’s stock after acquiring an additional 708 shares […] - 2025-04-21 04:56:57
StockNews.com Downgrades NovoCure (NASDAQ:NVCR) to Sell
NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday. Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares […] - 2025-04-11 05:18:59
Pictet Asset Management Holding SA Boosts Stake in NovoCure Limited (NASDAQ:NVCR)
Pictet Asset Management Holding SA boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,919 shares of the medical equipment provider’s stock after acquiring an additional […] - 2025-04-10 05:37:15
21,600 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS acquired a new stake in NovoCure Limited (NASDAQ:NVCR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,600 shares of the medical equipment provider’s stock, valued at approximately $644,000. A number of other hedge funds have also modified their holdings of […] - 2025-04-02 05:16:54
NovoCure Limited (NASDAQ:NVCR) Receives $35.80 Consensus PT from Analysts
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-03-24 04:40:48
NovoCure (NASDAQ:NVCR) Raised to “Hold” at StockNews.com
NovoCure (NASDAQ:NVCR – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday. Other analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of NovoCure in a […] - 2025-03-20 03:44:55
Charles Schwab Investment Management Inc. Purchases 11,771 Shares of NovoCure Limited (NASDAQ:NVCR)
Charles Schwab Investment Management Inc. boosted its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 836,214 shares of the medical equipment provider’s stock after buying an additional 11,771 shares during the period. […] - 2025-03-19 05:52:57
SBI Securities Co. Ltd. Invests $70,000 in NovoCure Limited (NASDAQ:NVCR)
SBI Securities Co. Ltd. acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,341 shares of the medical equipment provider’s stock, valued at approximately $70,000. Several other institutional investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group bought […] - 2025-03-10 06:07:07

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc NVCR holdings

DateNumber of NVCR Shares HeldBase Market Value of NVCR SharesLocal Market Value of NVCR SharesChange in NVCR Shares HeldChange in NVCR Base ValueCurrent Price per NVCR Share HeldPrevious Price per NVCR Share Held
2025-09-26 (Friday)64,057USD 825,695USD 825,695
2025-09-25 (Thursday)64,057USD 818,648NVCR holding decreased by -3844USD 818,6480USD -3,844 USD 12.78 USD 12.84
2025-09-24 (Wednesday)64,057USD 822,492USD 822,492
2025-09-17 (Wednesday)63,641USD 807,604NVCR holding increased by 636USD 807,6040USD 636 USD 12.69 USD 12.68
2025-09-16 (Tuesday)63,641USD 806,968USD 806,968
2025-09-12 (Friday)63,225USD 768,184USD 768,184
2025-09-11 (Thursday)63,225NVCR holding increased by 832USD 804,854NVCR holding increased by 18702USD 804,854832USD 18,702 USD 12.73 USD 12.6
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NVCR by Blackrock for IE00B3VWM098

Show aggregate share trades of NVCR

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY832 12.730* 18.90
2025-08-21SELL-175 11.910* 18.94 Profit of 3,315 on sale
2025-07-31BUY525 11.570* 19.03
2025-06-30SELL-350 17.800* 19.39 Profit of 6,786 on sale
2025-06-25SELL-175 17.325* 19.43 Profit of 3,400 on sale
2025-06-20SELL-350 16.690* 19.49 Profit of 6,820 on sale
2025-05-23BUY175 18.540* 19.77
2025-05-19SELL-175 17.960* 19.83 Profit of 3,470 on sale
2025-05-15SELL-525 17.590* 19.87 Profit of 10,431 on sale
2025-05-12SELL-175 18.570* 19.92 Profit of 3,486 on sale
2025-05-09SELL-175 17.380* 19.94 Profit of 3,490 on sale
2025-04-30SELL-175 18.140* 20.11 Profit of 3,519 on sale
2025-04-24SELL-350 18.550* 20.18 Profit of 7,063 on sale
2025-04-17SELL-175 15.580* 20.39 Profit of 3,568 on sale
2025-04-15SELL-525 16.460* 20.48 Profit of 10,753 on sale
2025-04-14SELL-525 16.550* 20.53 Profit of 10,776 on sale
2025-04-09SELL-700 16.950* 20.66 Profit of 14,464 on sale
2025-04-07SELL-1,225 16.610* 20.77 Profit of 25,445 on sale
2025-04-04SELL-1,750 16.490* 20.82 Profit of 36,438 on sale
2025-03-31BUY175 17.820* 20.93
2025-03-19SELL-350 19.320* 21.13 Profit of 7,397 on sale
2025-03-14SELL-1,050 19.490* 21.20 Profit of 22,264 on sale
2025-03-13SELL-352 20.060* 21.22 Profit of 7,469 on sale
2025-03-12SELL-5,984 20.620* 21.23 Profit of 127,033 on sale
2025-03-07SELL-352 20.180* 21.26 Profit of 7,483 on sale
2025-03-06SELL-528 19.260* 21.29 Profit of 11,240 on sale
2025-03-03SELL-176 18.410* 21.42 Profit of 3,770 on sale
2025-02-28BUY9,342 19.070* 21.46
2025-02-26SELL-148 21.960* 21.49 Profit of 3,180 on sale
2025-02-25SELL-444 21.000* 21.50 Profit of 9,544 on sale
2025-02-18BUY740 22.050* 21.47
2025-02-13BUY148 21.710* 21.42
2025-02-12BUY148 21.370* 21.43
2025-02-11BUY444 21.210* 21.43
2025-02-06BUY1,332 22.930* 21.37
2025-01-30BUY4,864 25.510* 21.00
2025-01-27BUY134 25.380* 20.64
2024-12-30BUY670 30.080* 19.71
2024-12-06BUY536 27.960* 18.80
2024-12-05BUY134 26.600* 18.53
2024-12-04BUY670 29.230* 18.15
2024-11-29BUY670 20.040* 17.11
2024-11-27BUY536 19.690* 16.88
2024-11-26BUY134 17.880* 16.84
2024-11-21BUY670 17.090* 16.68
2024-11-20BUY402 16.860* 16.67
2024-11-18BUY1,608 15.730* 16.74
2024-11-12BUY1,072 17.820* 16.66
2024-11-08BUY665 17.440* 16.61
2024-11-07BUY1,995 17.650* 16.53
2024-11-06BUY266 18.100* 16.40
2024-10-31BUY133 15.180* 16.53
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NVCR

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19146,2960421,75934.7%
2025-09-18109,1880560,45619.5%
2025-09-17119,469301498,06724.0%
2025-09-16191,175400705,46927.1%
2025-09-15272,06701,107,08324.6%
2025-09-12109,8570270,87440.6%
2025-09-11218,1160689,64231.6%
2025-09-10230,95395658,89035.1%
2025-09-09234,0444,681645,30736.3%
2025-09-08339,7253,440815,44541.7%
2025-09-05166,8920408,14640.9%
2025-09-04257,67243,716678,81638.0%
2025-09-03177,1140351,31950.4%
2025-09-02137,4000404,38934.0%
2025-08-29160,7270352,26345.6%
2025-08-28191,5783,553657,42329.1%
2025-08-27150,5517,255425,99235.3%
2025-08-26119,5160645,27618.5%
2025-08-25171,8120553,31531.1%
2025-08-2294,3000476,26219.8%
2025-08-21143,6200367,65139.1%
2025-08-20190,862110434,32643.9%
2025-08-19137,8590457,52230.1%
2025-08-18179,0560473,96137.8%
2025-08-15169,5698564,35130.0%
2025-08-14212,0810504,69142.0%
2025-08-13268,07401,199,25822.4%
2025-08-12212,7134,365614,71134.6%
2025-08-11194,2034512,17337.9%
2025-08-08254,9961,239736,77534.6%
2025-08-07243,762608804,78430.3%
2025-08-06229,7403,802734,19031.3%
2025-08-05463,4961,0612,536,45118.3%
2025-08-04323,99353954,16734.0%
2025-08-01378,47201,053,48535.9%
2025-07-31479,0082,5161,888,14425.4%
2025-07-30452,34501,441,40131.4%
2025-07-29329,6081,5021,070,20230.8%
2025-07-28306,60501,104,40427.8%
2025-07-25533,02442,5631,609,83133.1%
2025-07-24763,75871,5742,115,33136.1%
2025-07-23145,473921417,90734.8%
2025-07-22113,9980328,85534.7%
2025-07-21140,3120474,58129.6%
2025-07-1896,636400339,93628.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.